A Multi-centre, Randomised, Open-label, Cross-over Study to Explore Effectiveness, Safety, and Preference of a New Disposable Pen PDS290 Versus FlexPen in Subjects With Type 1 or Type 2 Diabetes

Trial Profile

A Multi-centre, Randomised, Open-label, Cross-over Study to Explore Effectiveness, Safety, and Preference of a New Disposable Pen PDS290 Versus FlexPen in Subjects With Type 1 or Type 2 Diabetes

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin detemir (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Jan 2012 Official title amended as reported by ClinicalTrials.gov.
    • 16 Oct 2009 Actual patient number changed from 256 to 255 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top